First Bank & Trust lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 38.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 40,390 shares of the biopharmaceutical company’s stock after acquiring an additional 11,233 shares during the period. First Bank & Trust’s holdings in Bristol-Myers Squibb were worth $2,090,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in BMY. ESL Trust Services LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth approximately $27,000. LGT Financial Advisors LLC raised its position in Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 227 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in Bristol-Myers Squibb during the 3rd quarter worth $34,000. MFA Wealth Advisors LLC acquired a new position in Bristol-Myers Squibb in the second quarter valued at $39,000. Finally, Beach Investment Counsel Inc. PA acquired a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $42,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.
Bristol-Myers Squibb Price Performance
BMY stock traded down $1.00 on Friday, hitting $51.92. 7,127,425 shares of the company’s stock traded hands, compared to its average volume of 14,553,149. The stock has a market cap of $105.25 billion, a price-to-earnings ratio of -16.75, a P/E/G ratio of 13.75 and a beta of 0.46. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $55.29. The stock has a fifty day moving average of $50.75 and a 200-day moving average of $46.44. The company has a current ratio of 1.16, a quick ratio of 1.02 and a debt-to-equity ratio of 2.86.
Bristol-Myers Squibb Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.62%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the company. TD Cowen increased their price target on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 23rd. Cantor Fitzgerald reissued a “neutral” rating and set a $50.00 price target on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Sanford C. Bernstein initiated coverage on Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 price objective on the stock. Finally, Barclays raised their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. Two investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $53.31.
Read Our Latest Report on Bristol-Myers Squibb
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Bristol-Myers Squibb
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Investors Need to Know About Upcoming IPOs
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 10/21- 10/25
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.